hypaque 85%
sanofi-synthelabo ireland ltd - meglumine amidotrizoate sodium amidotrizoate - 20 millilitre
urografin
he clissmann - meglumine amidotrizoate sodium amidotrizoate -
urografin 60%
he clissmann - meglumine amidotrizoate sodium amidotrizoate - 20 millilitre
urografin 76%
he clissmann - meglumine amidotrizoate sodium amidotrizoate - 20 millilitre
urografin 76%
he clissmann - meglumine amidotrizoate sodium amidotrizoate - 40 millilitre
flunixin meglumine
neove pharma australia pty limited - flunixin meglumine - unknown - flunixin meglumine benzene active 0.0 - active constituent
flunixin meglumine
mavlab pty. ltd. - flunixin meglumine - unknown - flunixin meglumine benzene active 0.0 - active constituent
gadopentetate dimeglumine injection, usp solution
jubilant draximage inc. dba jubilant radiopharma - gadopentetate dimeglumine - solution - 469mg - gadopentetate dimeglumine 469mg - other diagnostic agents
hexasol- oxytetracycline, flunixin meglumine injection, solution
norbrook laboratories limited - oxytetracycline (unii: x20i9en955) (oxytetracycline - unii:x20i9en955), flunixin meglumine (unii: 8y3jk0jw3u) (flunixin - unii:356ib1o400) - oxytetracycline 300 mg in 1 ml - for the treatment of bacterial pneumonia associated with pasteurella spp. and for the control of associated pyrexia in beef and non-lactating dairy cattle. do not use in animals showing hypersensitivity to either flunixin meglumine or oxytetracycline.
conray- iothalamate meglumine injection
liebel-flarsheim company llc - iothalamate meglumine (unii: xuw72gop7w) (iothalamic acid - unii:16chd79mix) - iothalamate meglumine 600 mg in 1 ml - conray is indicated for use in excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, intravenous digital subtraction angiography and arterial digital subtraction angiography. conray may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space. continuous or multiple scans separated by intervals of 1 to 3 seconds during the first 30 to 90 seconds post-injection of the contrast medium (dynamic ct scanning) may provide enhancement of diagnostic significance, and may be of benefit in establishing diagnoses of certain lesions in these sites with greater assurance than is possible with ct alone, and in supplying additional features of the lesions. in oth